In this multi-center prospective observational study, the investigators plan to identify the incidence and risk factors for checkpoint inhibitor-induced liver injury and characterize biochemical, genetic, immunological, and histological features associated with it.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of checkpoint inhibitor-induced liver injury (ChILI) and other immune-mediated adverse reactions
Timeframe: 3 years
Identify novel biomarkers associated with the diagnosis of ChILI
Timeframe: 3 years
Guruprasad Padur Aithal, MBBS, FRCP, PhD